WIL Research Laboratories

Last updated
WIL Research Laboratories
Type Private
Industry Pharmaceutical/biotechnology/agrochemical
Founded1976;47 years ago (1976)
FounderG. Bruce Briggs, DVM
SuccessorCharles River Laboratories Ashland, LLC
Headquarters Ashland, Ohio
Key people
 Joseph F. Holson, PhD, DABFE (President [1988-2008] during sustained organic growth phase)
Services
Number of employees
1,300 [1]  (2016)

WIL Research Laboratories, LLC (acquired in 2016 and renamed Charles River Laboratories Ashland, LLC) [2] was a contract research organization (CRO), privately held for 40 years, that provided product safety toxicological research, metabolism, bioanalytical, pharmacological, and formulation services to the pharmaceutical, biotechnology, chemical, agrochemical, and food products industries, as well as manufacturing support for clinical trials. WIL Research was well-known internationally in many disciplines, and considered by many industry experts to be the premier laboratory in the world for developmental and reproductive toxicology (DART). [3]

Contents

Early history

WIL Research Laboratories was founded in 1976 in Cincinnati, Ohio by G. Bruce Briggs, Ralph S. Hodgdon, and Robert W. Brigham, with Dr. Briggs serving as the company's first president.[ citation needed ] The company was initially a limited mammalian toxicological testing laboratory that conducted short-term studies for several clients in the Cincinnati area. In 1978, Great Lakes Chemical Corporation acquired WIL Research Laboratories. [4] By 1980, WIL Research outgrew its facilities in Cincinnati, subsequently acquired the 75-acre Hess & Clark research facility on the outskirts of Ashland, Ohio, and by 1982 had moved its operations to the new location. [5] The move to Ashland enabled WIL to conduct a larger number of studies as it began to expand its client base. [6]

Sustained organic growth

Dr. Joseph F. Holson was named President and Director of WIL Research Laboratories in 1988. Under his leadership over the next 20 years, WIL Research grew from 31 employees into a dynamic contract research organization employing more than 600 individuals at the Ashland site. [7] This success was attributed to the company's entrepreneurial scientific management, study director-centric business model, internationally recognized scientific prowess (particularly in DART), internally developed innovations (including the industry's first protocol-driven toxicology data management software system), and strong involvement in the Ashland community. [7] [8]

Entrepreneurial scientific management

During Holson's tenure, WIL Research continuously expanded its scientific capabilities, facilities, and staffing levels. During this period, the company grew from a limited mammalian toxicology research laboratory into a robust interdisciplinary CRO offering developmental and reproductive toxicology, neurotoxicology, inhalation toxicology, developmental neurotoxicology, large animal toxicology, juvenile toxicology, safety pharmacology, metabolism, analytical and bioanalytical chemistry, and formulation services to a globally diverse client base. [9] Underpinning the continuous expansion of service capabilities was a steady expansion of the company's facilities from approximately 30,000 square feet to more than 300,000 square feet of dedicated laboratory, vivarium, and support services space. [7]

At the heart of Dr. Holson's vision, though, was a drive to continually deepen the company's talent pool, as the number of employees in Ashland grew from 31 to more than 600. Joseph Holson was well-known as an energetic, outgoing leader with a vision for the company that revolved around the success of his staff and ongoing recruitment efforts. [7] Critical to the success of WIL Research was a continuous investment in staff training, as new biologists typically underwent a 9-12 month training period and all employees regularly completed continuing education not only in their specific areas of expertise but also in the subjects of animal care and welfare, Good Laboratory Practices, and research integrity. [7] [8] Many of the internal training programs developed at WIL Research were highly regarded and requested by clients and industry partners.

Study director-centric business model

A key driver of WIL's steady growth was its study director-centric business model, which viewed each study director as an individual business unit with scientific, project management, and marketing responsibilities. This approach was in contrast to the typical division within CROs between science and marketing. WIL Research emphasized direct scientist-to-scientist interaction as much as possible across the entire scope of each project, which gained the company numerous accolades from its clients. [10] Examples of the types of projects undertaken by WIL Research included studies of drugs for the treatment of herpes, Alzheimers' disease, glaucoma, cancer, and AIDS, numerous pesticides, and replacement chemicals for ozone-depleting chlorofluorocarbons in fire extinguishers. [8]

Global leadership in developmental and reproductive toxicology

Although highly respected in many disciplines, WIL Research was considered by many to be the leading laboratory in the world for developmental and reproductive toxicology (DART). [3] This leadership was driven by Dr. Joseph Holson, an internationally recognized authority in the field. The DART division at WIL Research, led initially by Dr. Holson and subsequently by Mr. Mark D. Nemec and Dr. Donald G. Stump, became known not only for high-quality regulatory guideline studies, but also for innovative, specialized DART research.

Internal innovation

In 1978, as a result of expanding toxicology testing services, the WIL Toxicology Data Management System (WTDMS™) was developed. [6] This protocol-driven software system was the first in the CRO industry and became the prototype for other major toxicology testing laboratories. [8] WTDMS™ was licensed to several other toxicology testing laboratories, and was used continuously by WIL Research Laboratories for nearly forty years prior to its gradual replacement by the Provantis system. [11]

Ashland Community

While WIL Research depended on the broader Ashland area for a steady supply of qualified personnel, it also contributed extensively to Ashland's economic growth, becoming one of the largest employers in the county. [5] [7] [10] During Holson's tenure, the company invested approximately $62 million in facilities renovation and expansion. In a talk given to the local Rotary club, Holson added that WIL Research at that time served approximately 550 clients (domestic and international), most of whom regularly visited Ashland to monitor their studies. In 2006, WIL Research received the Golden Oak award from the mayor of Ashland, an award recognizing "the foresight, diligence and unselfishness of individuals or organizations who contribute to new growth, strengthen the roots or improve the overall community of Ashland." [12]

WIL Research also actively supported Ashland University, with many of its senior scientists serving as adjunct professors in their areas of expertise, especially in the undergraduate toxicology program, which the company helped begin in 1984. [8] [13] [14] Dr. Joseph Holson also served on Ashland University's Science Advisory Board (1990-2008) and Board of Trustees (1993-1998), and gave the initial lecture, entitled "Risk and Regulation," of a year-long lecture series in support of the university's Environmental Studies program in 1995. [15]

Mergers and acquisitions

After nearly two decades of sustained organic growth, Joseph Holson led WIL Research through an initial period of private capital-financed expansion. In 2004, Holson and four other senior executives (Mark D. Nemec, Dr. Christopher P. Chengelis, Dr. Daniel W. Sved, and James M. Rudar) initiated a management buyout (in partnership with private equity firm Behrman Capital) from Great Lakes Chemical Corporation which led to the formation of a holding company (WRH, Inc.). [16] The expansion continued with the merger of Biotechnics, LLC (Hillsborough, NC, led by Dr. George Parker) with WIL Research operations in Ashland, the acquisitions of Notox Beheer BV ('s-Hertogenbosch, Netherlands, let by Jan van der Hoeven, Dr. Wilbert Frieling, and Dr. Ilona Enninga) [17] and QS Pharma LLC (Boothwyn, PA), [18] and the subsequent $500 million sale of WRH, Inc. to American Capital, Ltd. (NASDAQ:ACAS) in 2007. [19] [20] After the sale to ACAS, Dr. Holson served as Vice President and Chief Scientific Officer of the global entity while continuing to serve as President and Director of WIL Research Laboratories in Ashland, Ohio until his retirement in November 2008. Upon Dr. Holson's retirement, Mr. Nemec was appointed President and Chief Operating Officer of the Ashland flagship facility, [21] and Dr. Chengelis was named Vice President and Chief Scientific Officer. [22]

Under the ownership of American Capital, David Spaight was named Chairman and CEO of the global holding company in 2010, which undertook a re-branding and global integration effort. [23] During the ACAS-led period, growth of the company occurred primarily through additional acquisitions, including those of Midwest BioResearch, LLC (Skokie, IL, led by Dr. Michael Schlosser) [24] and Ricerca Bioscience's pharmaceutical services facility in Lyon, France (led by Stéphane Bulle). [25] [26] In addition, a new safety assessment facility in Schaijk, Netherlands (close to the existing Den Bosch site) was opened in 2015 to augment the European operations. [27] These activities combined to increase the total number of employees in the global entity to more than 1300, with total 2015 revenues of $215 million. [2]

In early 2016, Wilmington, MA-based Charles River Laboratories International, Inc. (NYSE:CRL), led by James C. Foster, acquired the global holdings of WIL Research for $585 million in cash. [28] [29] The platform WIL Research Laboratories facility in Ashland, OH was subsequently renamed to Charles River Laboratories Ashland, LLC. [30]

Related Research Articles

<span class="mw-page-title-main">Symyx Technologies</span>

Symyx Technologies, Inc. was a company that specialized in informatics and automation products. Symyx provided software solutions for scientific research, including Enterprise Laboratory Notebooks and products for combinatorial chemistry. The software part of the business became part of Accelrys, Inc. in 2010 and then in 2014 this company merged with Dassault Systèmes. Symyx also offered laboratory robotics systems for performing automated chemical research, which in 2010 was spun out as Freeslate, Inc.

<span class="mw-page-title-main">Huntingdon Life Sciences</span> Contract research organisation

Huntingdon Life Sciences (HLS) was a contract research organisation (CRO) founded in 1951 in Cambridgeshire, England. It had two laboratories in the United Kingdom and one in the United States. With over 1,600 staff, it was until 2015 the largest non-clinical CRO in Europe. In September 2015, Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics and LSR associates merged into Envigo, which later sold off the CRO part.

<span class="mw-page-title-main">Labcorp Drug Development</span> Contract research organization

Labcorp Drug Development is a contract research organization (CRO) headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, the company is part of Labcorp, which employs more than 70,000 people worldwide. Labcorp Drug Development claims to provide the world's largest central laboratory network.

Ashland Inc. is an American chemical company headquartered in Wilmington, Delaware. The company traces its roots back to the city of Ashland, Kentucky, where it was headquartered from 1924 to 1999. The company has five wholly owned divisions, which include Chemical Intermediates and Solvents, Composites, Industrial Specialties, Personal and Home Care, & Pharmaceuticals, Food and Beverage, and Agriculture. Until 2017, the company was the primary manufacturer of Valvoline.

In the life sciences, a contract research organization (CRO) is a company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. A CRO may provide such services as biopharmaceutical development, biological assay development, commercialization, clinical development, clinical trials management, pharmacovigilance, outcomes research, and real world evidence.

Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry and offers support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.

<span class="mw-page-title-main">UCB (company)</span> Biopharmaceutical company

UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders, inflammatory disorders, and oncology.

<span class="mw-page-title-main">Genome Valley</span> Life Sciences in Telangana, India

Genome Valley is an Indian high-technology business district spread across 2,000-acre (8.1 km2)/(3.1 sq mi) in Hyderabad, India. It is located across the suburbs, Turakapally, Shamirpet, Medchal, Uppal, Patancheru, Jeedimetla, Gachibowli and Keesara. The Genome Valley has developed as a cluster for Biomedical research, training and manufacturing. Genome Valley is now into its Phase III, which is about 11 kms from the Phase I and II with the total area approximately 2,000-acre (8.1 km2).

Parexel International is an American provider of biopharmaceutical services. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling biopharmaceuticals on the market today. The company publishes the annual Parexel R&D Statistical Sourcebook, operates the Parexel-Academy, and councils all of the top 50 biopharmaceutical and top 30 biotechnology companies.

IQVIA, formerly Quintiles and IMS Health, Inc., is an American Fortune 500 and S&P 500 multinational company serving the combined industries of health information technology and clinical research. IQVIA is a provider of biopharmaceutical development, professional consulting and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including investment strategy and management consulting services. It has a network of more than 88,000 employees in more than 100 countries and a market capitalization of US$49 billion as of August 2021. As of 2023, IQVIA was reported to be one of the world's largest contract research organizations (CRO).

<span class="mw-page-title-main">Thermo Fisher Scientific</span> Provisioner of scientific consumables, equipment, and services

Thermo Fisher Scientific Inc. is an American supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).

Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American healthcare company headquartered in Burlington, North Carolina. It operates one of the largest clinical laboratory networks in the world, with a United States network of 36 primary laboratories. Before a merger with National Health Laboratory in 1995, the company operated under the name Roche BioMedical. Labcorp performs its largest volume of specialty testing at its Center for Esoteric Testing in Burlington, North Carolina, where the company is headquartered. As of 2018, Labcorp processes 2.5 million lab tests weekly.

<span class="mw-page-title-main">Toxicology testing</span> Biochemical process

Toxicology testing, also known as safety assessment, or toxicity testing, is the process of determining the degree to which a substance of interest negatively impacts the normal biological functions of an organism, given a certain exposure duration, route of exposure, and substance concentration. Toxicology testing is often conducted by researchers who follow established toxicology test protocosl for a certain substance, mode of exposure, exposure environment, duration of exposure, a particular organism of interest, or for a particular developmental stage of interest. Toxicology testing is commonly conducted during preclinical development for a substance intended for human exposure. Stages of in silico, in vitro and in vivo research are conducted to determine safe exposure doses in model organisms. If necessary, the next phase of research involves human toxicology testing during a first-in-man study. Toxicology testing may be conducted by the pharmaceutical industry, biotechnology companies, contract research organizations, or environmental scientists.

<span class="mw-page-title-main">Wolfe Laboratories</span>

Wolfe Laboratories, Inc. (WLI) was a contract research organization (CRO) headquartered in Woburn, Massachusetts. It provided research and development services as well as GLP analytical services for products in late discovery phase through early clinical phases of drug development. It served clients in New England, the US and internationally. Laboratory operations took place in a large 21,000-square-foot (2,000 m2) facility.

WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.

Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 5,400 people. Medpace's mission statement is "to accelerate the global development of safe and effective medical therapeutics" through its high science and disciplined operating approach that leverages local, regulatory, and deep therapeutic expertise across all major areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective. Operating under a full-service model, Medpace provides a therapeutically focused, integrated, global approach to clinical development. The company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.

AMRI is a contract research and manufacturing organization that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries. Founded in 1991, AMRI operates in the United States, Europe and Asia, with its headquarters located in Albany, New York. AMRI has announced deals and collaborations with such companies as Pfizer Inc., Merck & Co., Eli Lilly and Co., Takeda, Genentech, Bristol-Myers Squibb Co. and GE.

Joseph F. Holson, an American scientist, business executive, and educator in the disciplines of toxicology and product development, served as President of WIL Research Laboratories for 20 years (1988-2008). He is known for his contributions to the fields of developmental and reproductive toxicology (DART), pharmacokinetics, and risk assessment, including extensive experience with study design, data interpretation, and interspecies extrapolation of health effects data. He has served in numerous U.S. EPA/FDA advisory committees and as an expert toxicology witness. He was elected to two National Academy of Sciences toxicology committees. Dr. Holson is an editor and author of the textbook Regulatory Toxicology and an author of two significant chapters in the textbook Developmental and Reproductive Toxicology: A Practical Approach, Second Edition. Two of his peer-reviewed articles were recognized by the Risk Assessment Specialty Section of the Society of Toxicology as the Outstanding Published Papers Demonstrating an Application of Risk Assessment. He is the first author to receive this award in consecutive years for publications produced with two separate sets of coauthors.

<span class="mw-page-title-main">Scientist.com (company)</span> Network of e-commerce marketplaces

Scientist.com is a network of public and private e-commerce marketplaces that connect buyers and sellers of scientific research services. The company was founded in 2007 by Kevin Lustig, Chris Petersen and Andrew Martin and launched its first public research marketplace in September 2008.

ICON plc is an Irish headquartered Nasdaq listed multinational healthcare intelligence and clinical research organisation that provides consulting, clinical development and commercialisation services for the pharmaceutical industry. As of June 2023, ICON had approximately 41,160 employees in 108 locations spread across 53 countries.

References

  1. ↑ "Charles River Laboratories to Acquire WIL Research". The Boston Globe .
  2. 1 2 "Charles River Laboratories Completes the Acquisition of WIL Research" (Press release). 4 April 2016. Retrieved 9 September 2017.
  3. 1 2 "WIL Research Laboratories, LLC Acquires Midwest BioResearch, LLC. - Free Online Library". www.thefreelibrary.com. Retrieved 2017-09-20.
  4. ↑ "WIL announces ownership change". Ashland Times-Gazette. 6 October 2004.
  5. 1 2 "WIL Research utilizes area people resources". Ashland Times-Gazette. 15 September 1982.
  6. 1 2 "WIL Research Laboratories Company Profile". BioPortfolio. Retrieved 2017-09-11.
  7. 1 2 3 4 5 6 "25 Who Are Making a Difference. Featuring: Joseph Holson". Ashland Times-Gazette. 27 February 2007.
  8. 1 2 3 4 5 "You're in Good Company in Ohio: Featuring WIL Research Laboratories Inc". Forbes. 18 December 1995.
  9. ↑ "Archived copy of wilresearch.com". Archived from the original on 2008-06-08.
  10. 1 2 "WIL Research Labs to expand". Ashland Times-Gazette. 30 July 2003.
  11. ↑ "WIL Research Partners With Instem For Global Harmonization Project". www.biospace.com. Retrieved 2017-09-11.
  12. ↑ Edwards, Megan. "Chandler Systems, WIL honored/ Ashland businesses receive Golden Oak awards from mayor". Ashland Times. Retrieved 2017-09-13.
  13. ↑ "Ashland University Offers Unique Toxicology Degree Program | College of Arts & Sciences | Ashland University". www.ashland.edu. Retrieved 2017-09-20.
  14. ↑ "Ashland mayor fêtes two long-time city businesses". News-Journal (Mansfield, Ohio). 15 September 2006.
  15. ↑ "WIL president assesses chemical risk". Ashland Times-Gazette. 15 November 1995.
  16. ↑ "Great Lakes Chemical sells WIL Research Labs; allies with ChlorKing". www.waterworld.com. October 2004. Retrieved 2017-09-11.
  17. ↑ "Behrman Capital and Texas Pacific Group Announce Acquisition of NOTOX Beheer BV - Behrman Capital". Behrman Capital. 2005-07-27. Retrieved 2017-09-11.
  18. ↑ "WIL Research Acquires QS Pharma | Mergr". mergr.com. Retrieved 2017-09-11.
  19. ↑ Christ, Ginger. "Investment firm sells interest in WIL Research for $500 million". Ashland Times. Retrieved 2017-09-11.
  20. ↑ "Behrman Capital Sells WIL Research Laboratories in $500 Million Transaction - Behrman Capital". Behrman Capital. 2007-07-18. Retrieved 2017-09-12.
  21. ↑ "Nemec promoted to lead WIL Research Labs". Ashland Times. Retrieved 2017-09-11.
  22. ↑ "WIL promotes area man to chief scientific officer". Ashland Times. Retrieved 2017-09-11.
  23. ↑ "WIL Research Appoints David Spaight as Chief Executive Officer". www.businesswire.com (Press release). Retrieved 2017-09-11.
  24. ↑ "WIL Research Laboratories, LLC Acquires Midwest BioResearch, LLC". www.businesswire.com (Press release). Retrieved 2017-09-11.
  25. ↑ "WIL Research Acquires Ricerca Lyon". Contract Pharma. Retrieved 2017-09-11.
  26. ↑ Editors, Pharmaceutical Technology. "WIL Research Acquires Ricerca's Pharma Service Business in Lyon, France". www.pharmtech.com. Retrieved 2017-09-12.{{cite web}}: |last= has generic name (help)
  27. ↑ "WIL Research Opens New Facility in the Netherlands - NFIA". NFIA. 2015-12-04. Retrieved 2017-09-12.
  28. ↑ "Wilmington's Charles River Labs To Acquire WIL Research". Wilmington Apple. 2016-01-07. Retrieved 2017-09-11.
  29. ↑ "Charles River Laboratories Completes the Acquisition of WIL Research". www.businesswire.com. 4 April 2016. Retrieved 2017-09-11.
  30. ↑ "Charles River Laboratories Ashland, LLC | BioOhio". www.bioohio.com. Retrieved 2017-09-11.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.